-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
5-Fluorouracil-[15N2]
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/68941-95-7.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 68941-95-7 |
| Description | 5-Fluorouracil-[15N2] is the labelled analogue of 5-Fluorouracil. 5-Fluorouracil is a pyrimidine analog that inteferes DNA synthesis. It can be used as an antineoplastic agent and antimetabolite. |
Product Information
| Synonyms | 5-Fluorouracil-15N2; 5-Fluoro-2,4(1H,3H)pyrimidinedione-15N2; 2,4-Dihydroxy-5-fluoropyrimidine-15N2; 5-FU-15N2; 5-Fluoropyrimidine-2,4-diol-15N2; Adrucil-15N2; Arumel-15N2; Carac-15N2; Fluoroplex-15N2; Fluorouracil-15N2; Flurablastin-15N2; Queroplex-15N2 |
| IUPAC Name | 5-fluoro-(1,3-15N2)1H-pyrimidine-2,4-dione |
| Molecular Weight | 132.06 |
| Molecular Formula | C4H3F[15N]2O2 |
| Canonical SMILES | C1=C(C(=O)NC(=O)N1)F |
| InChI | InChI=1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)/i6+1,7+1 |
| InChIKey | GHASVSINZRGABV-AKZCFXPHSA-N |
| Melting Point | 282-286°C |
| Purity | 95% by HPLC; 98% atom 15N |
| Solubility | Soluble in DMSO (Slightly), Methanol (Very Slightly, Heated), Water (Slightly) |
| Appearance | Solid |
| Storage | Store at 2-8°C |
| Complexity | 199 |
| Exact Mass | 132.01200 |
| In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and Metabolic profiles of drugs. |
| PSA | 65.72000 |
| Target | Nucleoside Antimetabolite/Analog; HIV; Apoptosis; Endogenous Metabolite |
| XLogP3-AA | -0.9 |
